Biblio
Export 1157 results:
Author [ Title] Type Year Filters: First Letter Of Last Name is R [Clear All Filters]
“Risk Variants in Three Alzheimer's Disease Genes Show Association with EEG Endophenotypes.”, J Alzheimers Dis, vol. 80, no. 1, pp. 209-223, 2021.
, “Role of Executive Functions in the Conversion from Mild Cognitive Impairment to Dementia.”, J Alzheimers Dis, vol. 77, no. 2, pp. 641-653, 2020.
, “Role of Executive Functions in the Conversion from Mild Cognitive Impairment to Dementia.”, J Alzheimers Dis, vol. 77, no. 2, pp. 641-653, 2020.
, “Role of Glutamate and NMDA Receptors in Alzheimer's Disease.”, J Alzheimers Dis, vol. 57, no. 4, pp. 1041-1048, 2017.
, “The Role of Interferon-α in Neurodegenerative Diseases: A Systematic Review.”, J Alzheimers Dis, vol. 94, no. s1, pp. S45-S66, 2023.
, “Role of Niemann-Pick Type C Disease Mutations in Dementia.”, J Alzheimers Dis, vol. 55, no. 3, pp. 1249-1259, 2017.
, “The Role of Verb Fluency in the Detection of Early Cognitive Impairment in Alzheimer's Disease.”, J Alzheimers Dis, vol. 62, no. 2, pp. 611-619, 2018.
, “The Role of Verb Fluency in the Detection of Early Cognitive Impairment in Alzheimer's Disease.”, J Alzheimers Dis, vol. 62, no. 2, pp. 611-619, 2018.
, “The Role of Verb Fluency in the Detection of Early Cognitive Impairment in Alzheimer's Disease.”, J Alzheimers Dis, vol. 62, no. 2, pp. 611-619, 2018.
, “S-[18F]THK-5117-PET and [11C]PIB-PET Imaging in Idiopathic Normal Pressure Hydrocephalus in Relation to Confirmed Amyloid-β Plaques and Tau in Brain Biopsies.”, J Alzheimers Dis, vol. 64, no. 1, pp. 171-179, 2018.
, “S-[18F]THK-5117-PET and [11C]PIB-PET Imaging in Idiopathic Normal Pressure Hydrocephalus in Relation to Confirmed Amyloid-β Plaques and Tau in Brain Biopsies.”, J Alzheimers Dis, vol. 64, no. 1, pp. 171-179, 2018.
, “S-[18F]THK-5117-PET and [11C]PIB-PET Imaging in Idiopathic Normal Pressure Hydrocephalus in Relation to Confirmed Amyloid-β Plaques and Tau in Brain Biopsies.”, J Alzheimers Dis, vol. 64, no. 1, pp. 171-179, 2018.
, “Safety and Efficacy of Monoclonal Antibodies for Alzheimer's Disease: A Systematic Review and Meta-Analysis of Published and Unpublished Clinical Trials.”, J Alzheimers Dis, vol. 87, no. 1, pp. 101-129, 2022.
, “Secular Trends in Dementia Prevalence and Incidence Worldwide: A Systematic Review.”, J Alzheimers Dis, vol. 66, no. 2, pp. 653-680, 2018.
, “Selenium Levels in Serum, Red Blood Cells, and Cerebrospinal Fluid of Alzheimer's Disease Patients: A Report from the Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL).”, J Alzheimers Dis, vol. 57, no. 1, pp. 183-193, 2017.
, “Selenoprotein S Reduces Endoplasmic Reticulum Stress-Induced Phosphorylation of Tau: Potential Role in Selenate Mitigation of Tau Pathology.”, J Alzheimers Dis, vol. 55, no. 2, pp. 749-762, 2017.
, “Self- and Informant-Reported Memory Complaints: Frequency and Severity in Cognitively Intact Individuals and those with Mild Cognitive Impairment and Neurodegenerative Dementias.”, J Alzheimers Dis, vol. 65, no. 3, pp. 1011-1027, 2018.
, “Self-Perceived Quality of Life Among Patients with Alzheimer's Disease: Two Longitudinal Models of Analysis.”, J Alzheimers Dis, vol. 52, no. 3, pp. 999-1012, 2016.
, “Self-Reported Physical Activity is Associated with Tau Burden Measured by Positron Emission Tomography.”, J Alzheimers Dis, vol. 63, no. 4, pp. 1299-1305, 2018.
, “Self-Reported Physical Activity is Associated with Tau Burden Measured by Positron Emission Tomography.”, J Alzheimers Dis, vol. 63, no. 4, pp. 1299-1305, 2018.
, “Self-Reported Traumatic Brain Injury and Mild Cognitive Impairment: Increased Risk and Earlier Age of Diagnosis.”, J Alzheimers Dis, vol. 51, no. 3, pp. 727-36, 2016.
, “Sembragiline in Moderate Alzheimer's Disease: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Trial (MAyflOwer RoAD).”, J Alzheimers Dis, vol. 58, no. 4, pp. 1217-1228, 2017.
, “Sensing of Alzheimer's Disease and Multiple Sclerosis Using Nano-Bio Interfaces.”, J Alzheimers Dis, vol. 59, no. 4, pp. 1187-1202, 2017.
, “Serotonin Selective Reuptake Inhibitor Treatment Improves Cognition and Grey Matter Atrophy but not Amyloid Burden During Two-Year Follow-Up in Mild Cognitive Impairment and Alzheimer's Disease Patients with Depressive Symptoms.”, J Alzheimers Dis, vol. 65, no. 3, pp. 793-806, 2018.
, “Serum Adiponectin Levels, Neuroimaging, and Cognition in the Mayo Clinic Study of Aging.”, J Alzheimers Dis, vol. 53, no. 2, pp. 573-81, 2016.
,